Download presentation
Presentation is loading. Please wait.
PublishKelly Boyd Modified over 6 years ago
1
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non– Small Cell Lung Cancer Emily R. York, MS, Marileila Varella-Garcia, PhD, Tami J. Bang, MD, Dara L. Aisner, MD, PhD, D. Ross Camidge, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 7, Pages e85-e88 (July 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 (A) Sagittal computed tomography images demonstrating loculated ascites with peritoneal thickening progressing during osimertinib therapy. (B) Marked response after 4 months of combined therapy with osimertinib and crizotinib (sustained at 6 months). (C) Longitudinal depiction of serum carcinoembryonic antigen levels after commencement of combination therapy with osimertinib, 80 mg, and crizotinib (initially at 200 mg twice daily and then escalated to 250 mg twice daily after a rise in carcinoembryonic antigen level at 4 months). Journal of Thoracic Oncology , e85-e88DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.